- AACR abstract outlines the broad therapeutic potential of BT-001, an oncolytic virus encoding an anti-CTLA4 antibody
- Activity demonstrated across a wide range of solid cancers
- BT-001 leverages the combined strengths of BioInvent's n-CoDeR®/F.I.R.S.T(TM) platforms and Transgene's Invir.IO(TM) platform
- First human trial with BT-001 expected to start before the end of 2020
Strasbourg (France) and Lund (Sweden), May 15, 2020, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce new highly promising preclinical data demonstrating the broad therapeutic potential of BT-001, an anti-CTLA4 antibody-encoding oncolytic virus, against solid tumors. These data will be presented at the AACR 2020 Virtual Annual Meeting II.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer